Loading stock data…
GSK.L
LSE2,017pGBX-9.00p (-0.45%)
Market OpenUpdated 7:24 AM EDT
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GSK plc in the Healthcare sector is trading at 2,017p. The stock is currently 12% below its 52-week high of 2,282p, remaining 13.4% above its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why GSK.L maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price2,017p
Potential Upside
78.6%
Whystock Fair Value3,602p
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Hold
Mean target2,049p+1.6%
Range1,455p – 2,750p
Fundamentals
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
£82.87B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.93
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Strong income play. Yield provides a meaningful total return floor.
346.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
43.31%
Volume
Today's trading volume
938,873
Recent News
4DMedical GSK Lung Imaging Deal And What It May Mean For Investors
4DMedical (ASX:4DX) has signed a contract with GlaxoSmithKline to supply quantitative lung imaging analytics. The agreement focuses on using 4DMedical’s technology in GSK’s drug development programs. The deal marks further commercial traction for 4DMedical’s proprietary respiratory imaging platform with a major global pharmaceutical company. 4DMedical focuses on respiratory imaging analytics, aiming to give drug developers more granular insight into lung function than traditional scans...
European Commission Approves MRNA's COVID-19-Influenza Combo Shot
Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines.
GSK (GSK) Earnings Expected to Grow: Should You Buy?
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK Respiratory Breakthrough And Pipeline Advances Reshape Long Term Outlook
GSK (LSE:GSK) secured multi region regulatory approvals in China and the European Union for depemokimab, branded as Exdensur, as a first in class ultra long acting biologic for certain respiratory conditions. The new approvals expand the global commercial footprint of depemokimab across key markets. The company also reported positive phase 1 data for Mo Rez, a B7 H4 targeted antibody drug conjugate in hard to treat gynecologic cancers. GSK highlighted progress on AlpE, a partnered...
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
MIRM heads into Q1 earnings with Livmarli sales in focus after 69% year-over-year growth in 2025. Bile acid products broaden revenue momentum.